Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CUE
stocks logo

CUE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.75M
+11.04%
-0.100
-21.87%
2.50M
+493.82%
-0.110
-35.29%
2.50M
-15.37%
-0.120
+33.33%
Estimates Revision
The market is revising No Change the revenue expectations for Cue Biopharma, Inc. (CUE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -29.10%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-29.10%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Cue Biopharma Inc (CUE.O) is -1.23, compared to its 5-year average forward P/E of -3.62. For a more detailed relative valuation and DCF analysis to assess Cue Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.62
Current PE
-1.23
Overvalued PE
-1.06
Undervalued PE
-6.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.64
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.99
Undervalued EV/EBITDA
-4.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
44.81
Current PS
0.00
Overvalued PS
102.04
Undervalued PS
-12.43
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CUE News & Events

Events Timeline

(ET)
2025-11-13
13:19:56
Cue Biopharma and ImmunoScape Sign Exclusive In-Licensing Agreement
select
2025-11-12 (ET)
2025-11-12
16:42:20
Cue Biopharma announces Q3 earnings per share of 7 cents, below consensus estimate of 9 cents.
select
2025-11-06 (ET)
2025-11-06
08:39:13
Cue Biopharma and ImmunoScape Forge Strategic Partnership and Licensing Agreement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11:00 AMNASDAQ.COM
Healthcare and Biotech Stocks Surge in After-Hours Trading: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

  • Sensei Biotherapeutics Surge: Sensei Biotherapeutics Inc. saw a significant after-hours increase of 62.9% to $17.20, following a previous rise and a report of a narrower third-quarter net loss compared to the previous year.

  • Praxis Precision Medicines Progress: Praxis Precision Medicines, Inc. rose 24.8% to $237.10 after positive EMBOLD study results led to an early recommendation for stopping the study, with plans for an NDA filing in early 2026.

  • CooperCompanies Financial Update: The CooperCompanies, Inc. climbed 13.0% to $87.01 after reporting a fourth-quarter net income decline but positive revenue growth, alongside a strategic review to enhance shareholder value.

  • Vanda Pharmaceuticals FDA Approval: Vanda Pharmaceuticals Inc. gained 7.5% to $5.59 after the FDA lifted a partial clinical hold on a protocol, allowing for expanded dosing of tradipitant following a successful dispute resolution request.

[object Object]
Preview
9.0
11-14Newsfilter
ImmunoScape, Based in Singapore, Leads Development of Advanced Cell Therapy for Solid Tumors; Reveals Major Licensing Agreement and New Board and SAB Appointments

  • Innovative Cancer Immunotherapy: ImmunoScape has partnered with Cue Biopharma to develop a new "Seed-and-Boost" immunotherapy approach that enhances T cell expansion and targets solid tumors, aiming to improve patient outcomes in various cancers.

  • Targeted Clinical Programs: The initial focus of ImmunoScape's clinical program is on the WT1 antigen, which is prevalent in several difficult-to-treat solid tumors, with plans to begin clinical trials by 2027 based on promising preclinical data.

  • Leadership Enhancements: ImmunoScape has strengthened its leadership team with key appointments, including experts from Cue Biopharma and other biotech firms, to drive innovation in cancer immunotherapy.

  • Support and Collaboration: The company acknowledges the support from local and global partners, including A*STAR and various investors, which has been crucial for its pioneering work in developing next-generation cancer treatments.

[object Object]
Preview
9.5
11-08NASDAQ.COM
CervoMed Inc. (CRVO) Announces Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Loss Report: CervoMed Inc. (CRVO) reported a quarterly loss of $0.84 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.68, and a significant decline from a loss of $0.55 per share a year ago.

  • Revenue Performance: The company generated revenues of $0.32 million for the quarter, missing the Zacks Consensus Estimate by 69.24% and down from $1.94 million in the same quarter last year.

  • Stock Performance and Outlook: Despite the disappointing earnings report, CRVO shares have increased by approximately 211.5% since the beginning of the year, outperforming the S&P 500's 14.3% gain, but the stock is currently rated as a Zacks Rank #3 (Hold).

  • Industry Context: The Medical - Biomedical and Genetics industry, to which CervoMed belongs, is ranked in the top 37% of Zacks industries, indicating a potentially favorable environment for stock performance, while investors are advised to monitor earnings estimate revisions for future guidance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cue Biopharma Inc (CUE) stock price today?

The current price of CUE is 0.553 USD — it has decreased -1.43 % in the last trading day.

arrow icon

What is Cue Biopharma Inc (CUE)'s business?

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

arrow icon

What is the price predicton of CUE Stock?

Wall Street analysts forecast CUE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CUE is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cue Biopharma Inc (CUE)'s revenue for the last quarter?

Cue Biopharma Inc revenue for the last quarter amounts to 2.15M USD, decreased -35.58 % YoY.

arrow icon

What is Cue Biopharma Inc (CUE)'s earnings per share (EPS) for the last quarter?

Cue Biopharma Inc. EPS for the last quarter amounts to -0.07 USD, decreased -58.82 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cue Biopharma Inc (CUE)'s fundamentals?

The market is revising No Change the revenue expectations for Cue Biopharma, Inc. (CUE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -29.10%.
arrow icon

How many employees does Cue Biopharma Inc (CUE). have?

Cue Biopharma Inc (CUE) has 41 emplpoyees as of December 05 2025.

arrow icon

What is Cue Biopharma Inc (CUE) market cap?

Today CUE has the market capitalization of 43.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free